THIABENDAZOLE

US Previously Marketed

First approved in 1967

Details

Stereochemistry	ACHIRAL
Molecular Formula	C10H7N3S
Molecular Weight	201.248
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

N1C(=NC2=C1C=CC=C2)C3=CSC=N3

InChI

InChIKey=WJCNZQLZVWNLKY-UHFFFAOYSA-N

InChI=1S/C10H7N3S/c1-2-4-8-7(3-1)12-10(13-8)9-5-14-6-11-9/h1-6H,(H,12,13)

HIDE SMILES / InChI

Molecular Formula	C10H7N3S
Molecular Weight	201.248
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/16096slr033,16097slr026_mintezol_lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/22927795

Thiabendazole (TBZ, trade names Mintezol, Tresaderm, and Arbotect) was first introduced in 1962. This drug is a fungicide and parasiticide and is indicated for the treatment of: strongyloidiasis (threadworm), cutaneous larva migrans (creeping eruption), visceral larva migrans, trichinosis: relief of symptoms and fever and a reduction of eosinophilia have followed the use of this drug during the invasion stage of the disease. But usage of this drug was discontinued. The precise mode of action of thiabendazole on the parasite is unknown, but it may inhibit the helminthspecific enzyme fumarate reductase. It was shown, also that thiabendazole reversibly disassembles newly established blood vessels, marking it as vascular disrupting agent (VDA) and thus as a potential complementary therapeutic for use in combination with current anti-angiogenic therapies. Was shown, that vascular disruption by TBZ results from reduced tubulin levels and hyper-active Rho signaling. In addition, was confirmed, that thiabendazole slowed tumor growth and decreased vascular density in preclinical fibrosarcoma xenografts and thus, it could lead directly to the identification of a potential new therapeutic application for an inexpensive drug that is already approved for clinical use in humans.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Tubulin 69 Target ID: CHEMBL2095182 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22927795	Inhibitor 8504
Fumarate reductase flavoprotein subunit 3 Target ID: O06913 Gene ID: 900116.0 Gene Symbol: frdA Target Organism: Helicobacter pylori (strain ATCC 700392 / 26695) (Campylobacter\|\|\|pylori) Sources: https://www.ncbi.nlm.nih.gov/pubmed/11031122	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Strongyloidiasis 10 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/16096slr033,16097slr026_mintezol_lbl.pdf	Curative	Approved 8583	MINTEZOL Approved Use MINTEZOL is indicated for the treatment of: Strongyloidiasis (threadworm) Cutaneous larva migrans (creeping eruption) Visceral larva migrans Trichinosis: Relief of symptoms and fever and a reduction of eosinophilia have followed the use of MINTEZOL during the invasion stage of the disease.Thiabendazole is usually inappropriate as first line therapy for enterobiasis (pinworm). However, when enterobiasis occurs with any of the conditions listed above, additional therapy is not required for most patients. MINTEZOL should be used only in the following infestations when more specific therapy is not available or cannot be used or when further therapy with a second agent is desirable: Uncinariasis (hookworm: Necator americanus and Ancylostoma duodenale); Trichuriasis (whipworm); Ascariasis (large roundworm). Launch Date 1967
Cutaneous larva migrans 3 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/16096slr033,16097slr026_mintezol_lbl.pdf	Curative	Approved 8583	MINTEZOL Approved Use MINTEZOL is indicated for the treatment of: Strongyloidiasis (threadworm) Cutaneous larva migrans (creeping eruption) Visceral larva migrans Trichinosis: Relief of symptoms and fever and a reduction of eosinophilia have followed the use of MINTEZOL during the invasion stage of the disease.Thiabendazole is usually inappropriate as first line therapy for enterobiasis (pinworm). However, when enterobiasis occurs with any of the conditions listed above, additional therapy is not required for most patients. MINTEZOL should be used only in the following infestations when more specific therapy is not available or cannot be used or when further therapy with a second agent is desirable: Uncinariasis (hookworm: Necator americanus and Ancylostoma duodenale); Trichuriasis (whipworm); Ascariasis (large roundworm). Launch Date 1967
Visceral larva migrans 3 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/16096slr033,16097slr026_mintezol_lbl.pdf	Curative	Approved 8583	MINTEZOL Approved Use MINTEZOL is indicated for the treatment of: Strongyloidiasis (threadworm) Cutaneous larva migrans (creeping eruption) Visceral larva migrans Trichinosis: Relief of symptoms and fever and a reduction of eosinophilia have followed the use of MINTEZOL during the invasion stage of the disease.Thiabendazole is usually inappropriate as first line therapy for enterobiasis (pinworm). However, when enterobiasis occurs with any of the conditions listed above, additional therapy is not required for most patients. MINTEZOL should be used only in the following infestations when more specific therapy is not available or cannot be used or when further therapy with a second agent is desirable: Uncinariasis (hookworm: Necator americanus and Ancylostoma duodenale); Trichuriasis (whipworm); Ascariasis (large roundworm). Launch Date 1967
Trichinosis 3 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/16096slr033,16097slr026_mintezol_lbl.pdf	Curative	Approved 8583	MINTEZOL Approved Use MINTEZOL is indicated for the treatment of: Strongyloidiasis (threadworm) Cutaneous larva migrans (creeping eruption) Visceral larva migrans Trichinosis: Relief of symptoms and fever and a reduction of eosinophilia have followed the use of MINTEZOL during the invasion stage of the disease.Thiabendazole is usually inappropriate as first line therapy for enterobiasis (pinworm). However, when enterobiasis occurs with any of the conditions listed above, additional therapy is not required for most patients. MINTEZOL should be used only in the following infestations when more specific therapy is not available or cannot be used or when further therapy with a second agent is desirable: Uncinariasis (hookworm: Necator americanus and Ancylostoma duodenale); Trichuriasis (whipworm); Ascariasis (large roundworm). Launch Date 1967

C_max

Value	Dose	Co-administered	Analyte	Population
5 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7050189/	25 mg/kg single, oral dose: 25 mg/kg route of administration: Oral experiment type: SINGLE co-administered:		THIABENDAZOLE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
0.9 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7050189/	25 mg/kg single, oral dose: 25 mg/kg route of administration: Oral experiment type: SINGLE co-administered:		THIABENDAZOLE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.17 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7050189/	25 mg/kg single, oral dose: 25 mg/kg route of administration: Oral experiment type: SINGLE co-administered:		THIABENDAZOLE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
25 mg/kg 2 times / day steady, oral Recommended Dose: 25 mg/kg, 2 times / day Route: oral Route: steady Dose: 25 mg/kg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15571478/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/15571478/	Other AEs: Asthenia, Epigastralgia... Other AEs: Asthenia (3 patients) Epigastralgia (1 patient) Disorientation (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/15571478/

AEs

AE	Significance	Dose	Population
Disorientation	1 patient	25 mg/kg 2 times / day steady, oral Recommended Dose: 25 mg/kg, 2 times / day Route: oral Route: steady Dose: 25 mg/kg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15571478/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/15571478/
Epigastralgia	1 patient	25 mg/kg 2 times / day steady, oral Recommended Dose: 25 mg/kg, 2 times / day Route: oral Route: steady Dose: 25 mg/kg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15571478/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/15571478/
Asthenia	3 patients	25 mg/kg 2 times / day steady, oral Recommended Dose: 25 mg/kg, 2 times / day Route: oral Route: steady Dose: 25 mg/kg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15571478/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/15571478/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 P-gp 1741 BSEP 550	CYP1A2 1197	CYP1A1 151

Drug as perpetrator

Target	Modality	Activity
BSEP 554	inhibitor 4027 Sources: https://onlinelibrary.wiley.com/doi/full/10.1002/jps.23584	no
CYP1A2 2333	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/16261361/	yes [Ki 1.54 uM]
CYP1A1 272	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/11226373/	yes
P-gp 1932	inhibitor 4027 Sources: https://www.phytojournal.com/archives/2019/vol8issue3/PartBH/8-3-541-743.pdf#page=1 Page: 1.0	yes

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP1A2 1197	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/9565779/	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:45979	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:45979
ChemicalBook	CB1685813	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB1685813
eMolecules	510269	https://www.emolecules.com/cgi-bin/more?vid=510269
MolPort	MolPort-001-002-054	https://www.molport.com/shop/molecule-link/MolPort-001-002-054
Selleck Chemicals	Thiabendazole	http://www.selleckchem.com/products/Thiabendazole.html
ZINC	ZINC000000073711	http://zinc15.docking.org/substances/ZINC000000073711

PubMed

Title	Date	PubMed
Fast and easy multiresidue method employing acetonitrile extraction/partitioning and "dispersive solid-phase extraction" for the determination of pesticide residues in produce.	2003-05-02	12723926
Severe drug rashes in three siblings simultaneously.	2003-05	12752334
[Toxocariasis: clinical and laboratory features in 54 patients].	2003-05	12724074
Fission yeast Rad26 responds to DNA damage independently of Rad3.	2003-04-03	12697061
Application of GRAM and TLD to the resolution and quantitation of real complex multicomponent mixtures by fluorescence spectroscopy.	2003-04	12707769
Treatment of cutaneous larva migrans and Toxocara infection.	2003-04	12667232
[A case of parasitism by Rhabditis sp in a child from Goiânia, Goiás, Brazil].	2003-03-08	12621674
A more selective medium for Culicinomyces clavisporus.	2003-03	12676556
Simple and rapid determination of thiabendazole, imazalil, and o-phenylphenol in citrus fruit using flow-injection electrospray ionization tandem mass spectrometry.	2003-02-12	12568539
[Strongyloidiasis].	2003-02	12722295
Antifungal agents of use in animal health--chemical, biochemical and pharmacological aspects.	2003-02	12603774
Ion trap tandem mass spectrometric identification of thiabendazole phototransformation products on titanium dioxide.	2003-01-10	12564676
A new role for the transcriptional corepressor SIN3; regulation of centromeres.	2003-01-08	12526748
[Selective vs. mass treatment with antihelminthic drugs: experience in two hyperendemic communities].	2003-01	12744797
Photomutagenicity of thiabendazole, a postharvest fungicide, in bacterial assays.	2003	12605377
Methods for generation of monoclonal antibodies to the very small drug hapten, 5-benzimidazolecarboxylic acid.	2002-12-20	12445730
Oxidative, heat and anthelminthic stress responses in four species of Trichinella: comparative study.	2002-12-01	12410594
Pesticide residues in biological waste.	2002-12	12489733
Development and validation of a liquid chromatographic-electrospray tandem mass spectrometric multiresidue method for anthelmintics in milk.	2002-11-08	12462609
Bud morphogenesis and the actin and microtubule cytoskeletons during budding in the corn smut fungus, Ustilago maydis.	2002-11	12409100
Characterization of a Schizosaccharomyces pombe strain deleted for a sequence homologue of the human damaged DNA binding 1 (DDB1) gene.	2002-10-25	12181326
The effects of stage-specific selection on the development of benzimidazole resistance in Haemonchus contortus in sheep.	2002-10-16	12383623
Massive infestation of cutanea larva migrans.	2002-10	12546776
Cytokinetic actomyosin ring formation and septation in fission yeast are dependent on the full recruitment of the polo-like kinase Plo1 to the spindle pole body and a functional spindle assembly checkpoint.	2002-09-15	12186944
Active ammonia excretion across the gills of the green shore crab Carcinus maenas: participation of Na(+)/K(+)-ATPase, V-type H(+)-ATPase and functional microtubules.	2002-09	12177142
Analysis and partial reversal of multidrug resistance to anthelmintics due to P-glycoprotein in Haemonchus contortus eggs using Lens culinaris lectin.	2002-09	12172813
The comet assay with 8 mouse organs: results with 39 currently used food additives.	2002-08-26	12160896
[Disseminated strongyloidiasis, a rare cause of multiple organ failure].	2002-08-10	12212512
Loeffler's syndrome and cutaneous larva migrans: a rare association.	2002-08	12174122
Opinion on the diagnosis and treatment of human trichinellosis.	2002-08	12150691
Cloning, production and characterisation of a recombinant Cu/Zn superoxide dismutase from Taenia solium.	2002-08	12117500
Induction of aneuploidy in male mouse germ cells detected by the sperm-FISH assay: a review of the present data base.	2002-07-25	12106657
Hyperinfective strongyloidiasis in the medical ward: review of 27 cases in 5 years.	2002-07	12144076
[Test treatment with antiparasitic agents for eosinophilia?].	2002-07	12139832
Validation of a method for the determination of multiclass pesticide residues in fruit juices by liquid chromatography/tandem mass spectrometry after extraction by matrix solid-phase dispersion.	2002-06-27	12083266
[A case of toxocariasis with eosinophil-rich pleural effusion].	2002-06	12325335
[DNA damage in female workers exposed to pesticides in banana plantations at Limón, Costa Rica].	2002-06	12298281
Yeast RSC function is required for organization of the cellular cytoskeleton via an alternative PKC1 pathway.	2002-06	12072455
Thiabendazole for the prophylaxis of strongyloidiasis in immunosuppressed patients with hematological diseases: a randomized double-blind placebo-controlled study.	2002-06	12031927
Anthelmintics: a review.	2002-04-20	11963321
Residue uptake and storage responses of Tarocco blood oranges after preharvest thiabendazole spray and postharvest heat treatment.	2002-04-10	11929286
The p21-activated kinase, Shk1, is required for proper regulation of microtubule dynamics in the fission yeast, Schizosaccharomyces pombe.	2002-04	11972773
Analysis of thiabendazole and procymidone in fruits and vegetables by capillary electrophoresis-electrospray mass spectrometry.	2002-03-08	11999753
Treatment failure in intestinal strongyloidiasis: an indicator of HTLV-I infection.	2002-03	12044298
Human strongyloidiasis in AIDS era: its zoonotic importance.	2002-03	11922234
Estimation of concentrations of antifungal agents allowed as food additives in foods and their daily intake based on official inspection results in Japan in fiscal year 1998.	2002-02	11998320
Evaluation of certain veterinary drug residues in food.	2002	12592988
Ecchymoses: an unusual manifestation of toxocariasis in children.	2001-12	12164030
[Toxocariasis].	2001-12	11908154
Parasitic infections of the intestine.	2001-10	11964880

Patents

Sample Use Guides

In Vivo Use Guide

The recommended maximum daily dose of MINTEZOL ((Thiabendazole) is 3 grams. MINTEZOL should be given after meals if possible. Tablets MINTEZOL should be chewed before swallowing. Dietary restriction, complementary medications and cleansing enemas are not needed. The usual dosage schedule for all conditions is two doses per day. The dosage is determined by the patient's weight.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:36:40 GMT 2025` Edited by `admin` on `Mon Mar 31 17:36:40 GMT 2025`
Record UNII	N1Q45E87DT
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TIABENDAZOLE

Preferred Name

English

THIABENDAZOLE

Official Name

English

THIABENDAZOLE [USP MONOGRAPH]

Common Name

English

LOMBRISTOP

Common Name

English

2-(4-Thiazolyl)benzimidazole

Systematic Name

English

THIABENDAZOLE [USP-RS]

Common Name

English

OMNIZOLE

Common Name

English

2-(THIAZOL-4-YL)BENZIMIDAZOLE

Systematic Name

English

MINZOLUM

Common Name

English

Tiabendazole [WHO-DD]

Common Name

English

1H-BENZIMIDAZOLE, 2-(4-THIAZOLYL)-

Systematic Name

English

THIABENZOLE

Common Name

English

THIABENDAZOLE [ORANGE BOOK]

Common Name

English

NSC-525040

Code

English

2-(4-THIAZOLYL)-1H-BENZIMIDAZOLE

Systematic Name

English

TIABENDAZOLE [WHO-IP]

Common Name

English

NEMAPAN

Common Name

English

PITRIZET

Common Name

English

THIABENDAZOLE [GREEN BOOK]

Common Name

English

THIABENDAZOLE [USAN]

Common Name

English

tiabendazole [INN]

Common Name

English

TIABENDAZOLE [MART.]

Common Name

English

THIABENDAZOLE [MI]

Common Name

English

TIABENDAZOLE [JAN]

Common Name

English

TIABENDAZOLE [EP MONOGRAPH]

Common Name

English

THIABENDAZOLE [VANDF]

Common Name

English

MK-360

Code

English

THIABENDAZOLE [HSDB]

Common Name

English

MINTEZOL

Brand Name

English

TIABENDAZOLE [EP IMPURITY]

Common Name

English

THIABENDAZOLE [ISO]

Common Name

English

NSC-90507

Code

English

Classification Tree Code System Code

WHO-ATC

P02CA02